ACADIA Pharmaceuticals Inc. (ACAD) Upgraded to Hold at Zacks Investment Research

Short resume:

company
90%
position
90%
analysts
90%
investment
90%

ACADIA Pharmaceuticals Inc. logo Zacks Investment Research upgraded shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) from a sell rating to a hold rating in a research note released on Friday, April 14th.
Source Sports Perspectives
Read More…

More News

Be the first to comment

Leave a Reply

Your email address will not be published.


*